Double Bond Pharmaceutical International AB-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Double Bond Pharmaceutical International AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014155
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Double Bond Pharmaceutical International AB (DBP) is a pharmaceutical company that develops and commercializes treatment of autoimmune diseases, cancers, infections, and other life-threatening disorders. The company’s products include proprietary platforms SA-033, SI-053, SA-042, and SA-083. Its temozolomide is an active pharmaceutical ingredient in temodex, which is an imidazotetrazine derivative of the alkylating agent dacarbazine. DBP also designs medicinal products for treating patients suffering from diseases such as cancer, inflammation, asthma and diabetes. The company’s ZIP-delivery platform provides a radical increase of the therapeutic value and is included in the development of products for treatment of different types of cancer and bacterial infections. Its temodex is a therapy to treat malignant brain tumors. DBP is headquartered in Uppsala, Sweden.

Double Bond Pharmaceutical International AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Double Bond Pharma Acquires Temodex from RI PCP 10
Partnerships 11
Double Bond Pharma Enters into Agreement with Romodanov Neurosurgery Institute 11
Double Bond Pharma Enters into Agreement with Uppsala University 12
Double Bond Pharmaceutical Expand Agreement with N.N. Alexandrov National Cancer 13
Double Bond Pharma Enters into Agreement with N.N. Alexandrov National Cancer Centre of Belarus 14
Double Bond Pharma Enters into Agreement with Research Institute of Bioorganic Chemistry 15
Licensing Agreements 16
Double Bond Pharma to Enter into Licensing Agreement for Temodex 16
Equity Offering 17
Double Bond Pharma to Raise USD0.3 Million in Private Placement of Shares 17
Double Bond Pharma Raises USD1 Million in Rights Offering of Shares 18
Double Bond Pharma Raises USD0.78 Million in Rights Offering of Shares 19
Double Bond Pharmaceutical International AB – Key Competitors 20
Double Bond Pharmaceutical International AB – Key Employees 21
Double Bond Pharmaceutical International AB – Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Product Approvals 23
Oct 26, 2016: The Annual report for Orphan Drug Designation status for SA-033 received no remarks from EMA 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Key Facts 2
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Double Bond Pharmaceutical International AB, Deals By Therapy Area, 2011 to YTD 2017 8
Double Bond Pharmaceutical International AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Double Bond Pharma Acquires Temodex from RI PCP 10
Double Bond Pharma Enters into Agreement with Romodanov Neurosurgery Institute 11
Double Bond Pharma Enters into Agreement with Uppsala University 12
Double Bond Pharmaceutical Expand Agreement with N.N. Alexandrov National Cancer 13
Double Bond Pharma Enters into Agreement with N.N. Alexandrov National Cancer Centre of Belarus 14
Double Bond Pharma Enters into Agreement with Research Institute of Bioorganic Chemistry 15
Double Bond Pharma to Enter into Licensing Agreement for Temodex 16
Double Bond Pharma to Raise USD0.3 Million in Private Placement of Shares 17
Double Bond Pharma Raises USD1 Million in Rights Offering of Shares 18
Double Bond Pharma Raises USD0.78 Million in Rights Offering of Shares 19
Double Bond Pharmaceutical International AB, Key Competitors 20
Double Bond Pharmaceutical International AB, Key Employees 21

★海外企業調査レポート[Double Bond Pharmaceutical International AB-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tieto Corporation:企業のM&A・事業提携・投資動向
    Tieto Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tieto Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • OptiNose US Inc (OPTN):製薬・医療:M&Aディール及び事業提携情報
    Summary OptiNose US Inc (OptiNose) is a specialty pharmaceutical company that develops and delivers new pipeline drugs through intranasal deposition of medications. The company offers products such as XHANCE fluticasone propionate and ONZETRA sumatriptan nasal powder. Its products are used in the th …
  • Nomura Holdings, Inc.:企業のM&A・事業提携・投資動向
    Nomura Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Nomura Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • NewLink Genetics Corp (NLNK):製薬・医療:M&Aディール及び事業提携情報
    Summary NewLink Genetics Corp (NewLink) is a clinical stage immuno-oncology company that discovers and develops novel immunotherapeutic products for the treatment of cancer. Its products include small-molecule and biologic immuno-oncology products. NewLink utilizes its HyperAcute cellular immunother …
  • Kaiser Foundation Health Plan of Washington:企業の戦略的SWOT分析
    Kaiser Foundation Health Plan of Washington - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • Selex Gruppo Commerciale S.p.A.:企業の戦略・SWOT・財務情報
    Selex Gruppo Commerciale S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Selex Gruppo Commerciale S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Combined Motor Holdings Ltd.:企業の戦略・SWOT・財務情報
    Combined Motor Holdings Ltd. - Strategy, SWOT and Corporate Finance Report Summary Combined Motor Holdings Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Enea SA (ENA):企業の財務・戦略的SWOT分析
    Enea SA (ENA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • pSivida Corp (PSDV)-製薬・医療分野:企業M&A・提携分析
    Summary pSivida Corp (pSivida) is a specialty pharmaceutical company that offers development of miniaturized, sustained-release drug delivery products and technologies. The company’s products include iluvien, retisert and durasert. Its durasert is an injectable, miniaturized, sustained-release drug …
  • XBiotech Inc (XBIT):製薬・医療:M&Aディール及び事業提携情報
    Summary XBiotech Inc (XBiotech) is a biopharmaceutical company that discovers, develops and commercialize therapeutic antibodies based proprietary technology. The company provides monoclonal antibodies treatment for various diseases. It’s lead product Xilonix, a therapeutic antibody being developed …
  • Iridex Corp (IRIX):医療機器:M&Aディール及び事業提携情報
    Summary Iridex Corp (Iridex) is a medical device company that manufactures and distributes laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology and otolaryngology market. The company offers products such as lasers, laser delivery devices, glaucoma device …
  • Kuros Biosciences Ltd (KURN)-製薬・医療分野:企業M&A・提携分析
    Summary Kuros Biosciences Ltd (Kuros Biosciences) is a biotechnology company that develops products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specificall …
  • Emera Inc:発電所・企業SWOT分析
    Emera Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executiv …
  • Global Imaging Systems, Inc.:企業のM&A・事業提携・投資動向
    Global Imaging Systems, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Global Imaging Systems, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • S.A. Industrias Celulosa Aragonesa:企業の戦略・SWOT・財務情報
    S.A. Industrias Celulosa Aragonesa - Strategy, SWOT and Corporate Finance Report Summary S.A. Industrias Celulosa Aragonesa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Mycenax Biotech Inc (4726):企業の財務・戦略的SWOT分析
    Summary Mycenax Biotech Inc (Mycenax) is a biopharmaceutical company that develops and manufactures pharmaceutical formulations. The company provides pipeline portfolio encompasses investigational candidates targeted at the treatment of plaque psoriasis, glioblastoma, asthma, adult crohn's Disease, …
  • Westar Energy Inc:企業の発電所・SWOT分析2018
    Westar Energy Inc - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Sangoma Technologies Corporation (STC):企業の財務・戦略的SWOT分析
    Sangoma Technologies Corporation (STC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Sigma-Tau HealthScience USA, Inc:企業の戦略・SWOT・財務情報
    Sigma-Tau HealthScience USA, Inc - Strategy, SWOT and Corporate Finance Report Summary Sigma-Tau HealthScience USA, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • SomaLogic Inc:企業の製品パイプライン分析
    Summary SomaLogic Inc (SomaLogic) is a life science company that discovers, develops and commercializes life science research tools and clinical diagnostic products. The company’s products include SOMAscan assay and SOMAmer reagents. Its SOMAscan reagents is a proteomic platform that combines the pr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆